Frazier Life Sciences Management L.P. Buys 793,200 Shares of Immatics (NASDAQ:IMTX)

Frazier Life Sciences Management L.P. increased its stake in shares of Immatics (NASDAQ:IMTX - Free Report) by 58.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,147,911 shares of the company's stock after acquiring an additional 793,200 shares during the quarter. Frazier Life Sciences Management L.P. owned about 1.80% of Immatics worth $15,272,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of IMTX. Suvretta Capital Management LLC bought a new stake in Immatics in the 4th quarter valued at $36,014,000. T. Rowe Price Investment Management Inc. increased its holdings in Immatics by 43.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,604,777 shares of the company's stock valued at $75,400,000 after buying an additional 3,225,141 shares during the period. Vestal Point Capital LP increased its holdings in Immatics by 67.3% in the 4th quarter. Vestal Point Capital LP now owns 6,275,000 shares of the company's stock valued at $44,615,000 after buying an additional 2,525,000 shares during the period. Braidwell LP increased its holdings in Immatics by 112.7% in the 4th quarter. Braidwell LP now owns 3,503,965 shares of the company's stock valued at $24,913,000 after buying an additional 1,856,400 shares during the period. Finally, Paradigm Biocapital Advisors LP increased its holdings in Immatics by 38.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 5,414,409 shares of the company's stock valued at $38,496,000 after buying an additional 1,509,547 shares during the period. Institutional investors own 64.41% of the company's stock.

Immatics Stock Performance

Shares of NASDAQ:IMTX opened at $5.40 on Wednesday. Immatics has a 52 week low of $3.30 and a 52 week high of $13.77. The company's fifty day moving average is $4.51 and its 200-day moving average is $5.79. The company has a market capitalization of $656.37 million, a PE ratio of -8.18 and a beta of 0.87.

Immatics (NASDAQ:IMTX - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. The company had revenue of $20.12 million for the quarter, compared to the consensus estimate of $14.92 million. On average, analysts forecast that Immatics will post -0.72 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an "overweight" rating on shares of Immatics in a report on Tuesday, April 1st.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.